DDInter927 DDInter489
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.
Deferiprone {u} (Compound) binds {v} (Gene) UGT1A6
Deferiprone {u} (Compound) upregulates {v} (Gene) BTK
Deferiprone {u} (Compound) is included by {v} (Pharmacologic Class) Iron Chelating Activity
Deferiprone {u} (Compound) downregulates {v} (Gene) HSPA8
Deferiprone {u} (Compound) causes {v} (Side Effect) Rash pustular
Deferiprone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium sulfate
Deferiprone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Deferiprone {u} may lead to a major life threatening interaction when taken with {v} Tioguanine
Deferiprone {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Deferiprone (Compound) binds UGT1A6 (Gene)
Deferiprone (Compound) upregulates BTK (Gene)
Deferiprone (Compound) is included by Iron Chelating Activity (Pharmacologic Class)
Deferiprone (Compound) downregulates HSPA8 (Gene)
Deferiprone (Compound) causes Rash pustular (Side Effect)
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Deferiprone may lead to a major life threatening interaction when taken with Tioguanine
Deferiprone may lead to a major life threatening interaction when taken with Rucaparib